Study of bimekizumab for kids with certain types of juvenile arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests a drug called bimekizumab in children and teens with specific types of juvenile arthritis (enthesitis-related arthritis or psoriatic arthritis). It aims to see how the drug works in the body and if it's safe. This may help those who haven't gotten enough relief from standard anti-inflammatory medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 17 years old.
- You must have a type of juvenile arthritis called enthesitis-related arthritis or juvenile psoriatic arthritis for at least 3 months.
- Your arthritis must be active, meaning you have at least 3 swollen joints and, if you have enthesitis-related arthritis, at least one tender spot where tendons attach to bone.
- You must have tried an NSAID (like ibuprofen or naproxen) for at least 1 month and it didn't work well enough or caused side effects.
- You must weigh at least 22 pounds (10 kilograms).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
This study tests a drug called secukinumab (given through an IV) in children with juvenile psoriatic arthritis. The goal is to see how well it works and if it's safe over time, for up to 6 years.
This study looks at whether giving bimekizumab in different ways is safe and how it moves through the body over time. It is for adults with active psoriatic arthritis or axial spondyloarthritis who may benefit from bimekizumab treatment.
This trial tests if the drug bimekizumab can slow down chronic inflammation in people with early plaque psoriasis. It's for adults 18-44 with mild psoriasis who haven't used topical treatments recently.
This study measures how much bimekizumab (Bimzelx) gets into breast milk. It helps us understand if the medicine is safe for breastfeeding babies whose mothers take this drug.
This trial tests a new drug, bimekizumab, for people with PRP, a rare skin condition. It may help reduce skin redness, scaling, and itching.
Hear when a new Juvenile Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.